



European Medicines Agency

Doc. Ref. EMA/815429/2009
P/254/2009

EUROPEAN MEDICINES AGENCY DECISION

of 22 December 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Belimumab (EMA-000520-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

EUROPEAN MEDICINES AGENCY DECISION

of 22 December 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Belimumab (EMA-000520-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Glaxo Group Limited on 30 January 2009 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation and a deferral under Article 20 of said Regulation,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 November 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

- (1) The Paediatric Committee of the European Medicines has given an opinion on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver,
- (2) It is therefore appropriate to adopt a Decision agreeing a Paediatric Investigation Plan.
- (3) It is therefore appropriate to adopt a Decision granting a deferral.
- (4) It is therefore appropriate to adopt a Decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1

² OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for Belimumab, powder for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for Belimumab, powder for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for Belimumab, powder for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Glaxo Group Limited, Glaxo Wellcome House, Berkeley Avenue, UB6 0NN Greenford.

Done at London, 22 December 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)



European Medicines Agency

Doc. Ref. EMEA/PDCO/722617/2009
EMEA-000520-PIP01-08

**OPINION OF THE PAEDIATRIC COMMITTEE ON THE AGREEMENT OF
A PAEDIATRIC INVESTIGATION PLAN AND A DEFERRAL AND A WAIVER**

Scope of the application

Active substance(s):

Belimumab

Condition(s):

Systemic lupus erythematosus

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Glaxo Group Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Glaxo Group Limited submitted for agreement to the EMA on 30 January 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 5 March 2009.

Supplementary information was provided by the applicant on 4 September 2009.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Articles 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix.

London, 13 November 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Systemic lupus erythematosus

B. WAIVER

- **Condition**

Systemic lupus erythematosus

The waiver applies to:

- Children from birth to less than 5 years
- for powder for solution for infusion, for intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Systemic lupus erythematosus

- **Proposed PIP indication**

Treatment of systemic lupus erythematosus

- **Subset(s) of the paediatric population concerned by the paediatric development**

From 5 to less than 18 years.

- **Formulation(s)**

Powder for solution for infusion, intravenous use

- **Studies**

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	1	Multicenter, randomized, placebo-controlled withdrawal trial to evaluate the efficacy, safety and pharmacokinetics of belimumab in paediatric patients with systemic lupus erythematosus

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2015
Deferral for some or all studies contained in the paediatric investigation plan:	Yes